Partnering
ACADIA is committed to the discovery and development of novel treatments for central nervous system (CNS) disorders. Our current clinical and preclinical programs all emanate from internal discoveries and are rooted in our scientific heritage and strength in CNS research.
Core to ACADIA's strategy is to selectively pursue strategic collaborations to advance and maximize the commercial potential of our pipeline. In therapeutic areas that involve a more extensive development program or address large primary care markets, we intend to complete late-stage clinical development and commercialization through, or in collaboration with, partners. In areas where our products can be sold by a specialty sales force that calls on a focused group of physicians, we may elect to participate in the commercialization of our product candidates. Additionally, for discoveries we have made beyond our most advanced programs and those that have applications outside our main focus area, we may explore partnerships earlier in the process to accelerate advancements of these programs.
To further explore partnering opportunities with ACADIA, please contact us at bd@acadia-pharm.com.
Current Partnerships
ACADIA has formed a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corp., to co-develop and commercialize pimavanserin for neurological and psychiatric indications, including Parkinson's disease psychosis and Alzheimer's disease psychosis, in North America. Pimavanserin is currently in Phase III development as a treatment for Parkinson's disease psychosis, Alzheimer's disease psychosis, and as a co-therapy for schizophrenia. In addition to an upfront payment and potential milestone payments and royalties on product sales, ACADIA has the option to co-promote pimavanserin in the United States. ACADIA retains the rights to pimavanserin in the rest of the world.
ACADIA has formed three separate collaborations with Allergan in the areas of pain and ophthalmology:
The first collaboration has resulted in the discovery of alpha adrenergic drug candidates for the treatment of chronic pain. This program is in Phase II development.
In the second collaboration, Allergan and ACADIA are focused on the development and commercialization of selective muscarinic drugs for the treatment of glaucoma. Allergan is conducting Phase I development in this program.
The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of ophthalmology.
ACADIA has formed a collaboration with Meiji Seika Kaisha to develop and commercialize a novel class of pro-cognitive drugs to treat patients with schizophrenia and related disorders in Japan and several other Asian countries. The collaboration is focused on developing a product candidate, AM-831, which was discovered by ACADIA and selected by the parties for IND-track development. ACADIA retains the rights to develop and commercialize the product in the rest of the world, including the U.S. and Europe.